Boehringer Ingelheim and Microsoft launch AI partnership to develop digital patient twins for clinical trials

Boehringer Ingelheim and Microsoft announced a collaboration to investigate AI driven digital patient twins that model individual patients for clinical trial design.

The work will explore disease progression modeling, predictive outcome modeling, patient stratification and advanced trial simulation to make trials more patient centric and efficient.

They hope digital twins could enable synthetic or hybrid control arms, potentially reducing the number of patients required in conventional control groups and accelerating evidence generation, but any application will require rigorous validation and regulatory acceptance.